1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Vitrolife AB (publ)

Vitrolife AB (publ)

VITR.ST
Vitrolife AB (publ)SE flagStockholm Stock Exchange
89.35
SEK
-1.75
- -
12.10BMarket Cap
Vitrolife AB (publ)
VITR.ST
(Stockholm Stock Exchange)

Recent

price

89.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.04
3.15
3.7
4.57
5.11
6.65
7.89
9.64
10.61
13.64
11.47
14.67
23.89
25.94
26.65
25.4
26.13
Revenue per Share
0.3
0.31
3.41
0.57
1.09
1.68
1.75
2.43
2.85
3.53
2.64
2.97
2.91
-28.44
3.79
-37.01
3.36
Basic EPS, GAAP
0.07
0.16
0.43
0.98
1.37
1.57
1.54
2.78
1.56
3.01
3.1
2.8
4.05
4.71
5.21
2.87
5.12
Free Cash Flow per Basic Share
0.1
0.12
0.14
0.12
0.2
0.3
0.48
0.53
0.75
0.85
- -
0.77
0.81
0.85
1
1.1
1.1
Dividend per Share
1.44
1.61
0.96
1.33
2.23
3.44
4.71
6.62
8.73
11.41
13.97
15.34
14.98
-14.51
-11.67
-49.67
-11.23
Book Value per Share
1.44
1.43
0.64
1.1
1.41
3.04
3.42
5.72
7.08
9.39
12.11
-19.25
-13.16
-8.72
-6.07
-2.83
-5.38
Tangible Book Value per Share
98
98
98
99
100
109
109
109
109
109
109
115
135
135
135
135
135
Basic Weighted Avg Shares
298
308
362
453
511
722
856
1,046
1,151
1,480
1,246
1,681
3,234
3,512
3,609
3,440
3,539
Sales/Revenue/Turnover
11.18
7.06
13.84
17.41
26.61
28.87
28.97
32.82
33.79
32.98
30.17
25.46
20.01
21.01
21.95
16.69
19.36
Operating Margin (%)
- -
17
19
35
23
53
54
67
85
99
84
109
396
425
442
427
61
Depreciation Expense
29
30
334
56
109
183
190
264
310
383
287
341
394
-3,851
513
-5,012
455
Net Income, GAAP
29.26
32.06
46.63
28.94
25.49
19.17
23.19
22.38
22.05
22.09
21.39
25.22
26.63
- -
23.74
- -
- -
Effective Tax Rate (%)
9.72
9.86
92.2
12.43
21.37
25.31
22.24
25.2
26.9
25.86
23.03
20.29
12.18
-109.65
14.21
-145.7
12.86
Profit Margin (%)
70
86
63
88
149
283
317
575
698
948
1,237
453
951
1,357
1,652
1,477
1,542
Working Capital
41
56
58
22
60
36
- -
- -
- -
61
49
2,026
2,043
1,942
1,929
1,562
1,840
LT Debt
326
344
279
316
703
845
1,020
1,229
1,496
1,798
2,017
15,341
16,740
12,723
13,641
7,895
13,282
Total Equity
6.72
3.7
6.82
15.34
17.12
19.35
18.98
22.93
21.95
22.25
14.83
3.21
2.58
- -
3.95
- -
4.48
Return on Invested Capital (%)
21.79
17.38
169
33.35
45.38
50.01
39.03
41.3
36.94
33.8
19.82
11.83
10.01
- -
183.55
- -
125.27
Return on Capital (%)
22.09
20.36
264.73
49.76
61.52
61.34
43.04
42.86
37.16
35.01
20.83
20.83
20.81
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
160
151
153
LT Borrowings
1,837
1,710
1,758
LT Finance Leases
92
90
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
29,113
21,829
18,959

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,357
2,279
2,183
Cash, Cash Equivalents & STI
1,135
1,054
921
Accounts Receivable, Net
648
634
635
Inventories
422
413
430
Total Current Liabilities
705
605
641
Payables & Accruals
- -
- -
- -
ST Debt
160
151
153
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.61%
122.16%
-42.12%
Free Cash Flow
17.82%
9.64%
-44.96%
Net Income, GAAP
-217.47%
-446.66%
-1,077%
Sales/Revenue/Turnover
19.75%
26.81%
-4.68%
Total Cash Common Dividend
- -
10.54%
10.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
841
941
867
959
3,609
2025
842
871
891
- -
3,440
2026
807
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.85
1.06
0.86
1.03
3.79
2025
0.74
0.74
-39.24
- -
-37.01
2026
0.75
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
- -
- -
1
2025
- -
1.1
- -
- -
1.1
2026
- -
- -
- -
- -
- -
Similar Companies
BrainsWay Ltd. (BWAY)
iXensor Co., Ltd. (6734.TWO)
Osstem Implant Co., Ltd. (048260.KQ)
GN Store Nord A/S (GN.CO)
PolyNovo Limited (PNV.AX)
Cochlear Limited (COH.AX)
Business
Vitrolife AB (publ) Vitrolife AB (publ) develops, manufactures and commercializes medical devices and genetic testing services for assisted reproduction technologies and reproductive health clinics worldwide; its core offerings encompass IVF media and consumables including sperm processing solutions, oocyte retrieval needles, micromanipulation pipettes, dishes, tubes and embryo handling tools; time-lapse incubation and imaging systems such as EmbryoScope with integrated evaluation software; laser systems for embryo manipulation; cryopreservation equipment including VitroTemp; and genetic testing services via its Igenomix subsidiary covering preimplantation genetic testing for aneuploidy, structural rearrangements and monogenic disorders. The company operates through three main geographic segments—EMEA, Americas and APAC—with primary revenue from EMEA; it serves IVF clinics, fertility centers and reproductive health providers targeting patients seeking fertility treatments. Founded in 1994 and headquartered in Gothenburg, Sweden, Vitrolife supports the full IVF workflow from gamete preparation and fertilization through embryo culture, evaluation, transfer and cryopreservation, emphasizing quality control, regulatory compliance including CE marking and FDA clearance, and sustainability initiatives like ISO 14001 certification at its production facilities. In recent developments, Vitrolife completed the acquisition of eFertility (STB Zorg B.V.) in 2024, integrating its witnessing system and electronic medical records platform to advance digitalization and standardization across IVF workflows as part of a five-year strategy for end-to-end solutions; the company also renewed a EUR 300 million loan agreement comprising term loans and revolving credit facilities to bolster financial flexibility. Q3 2025 sales grew 5% organically, driven by consumables performance amid resilient demand in Americas and EMEA regions, while Q2 2025 reported flat growth in local currencies with 3% organic expansion excluding discontinued operations. These moves enhance Vitrolife's portfolio in automation, innovation and global scalability within the reproductive health sector.